HALOZYME THERAPEUTICS, INC. cotiza a 109.62 USD y tiene una capitalización bursátil de $12.4B. En los últimos 12 meses ha facturado $1.7B con un margen de flujo de caja libre del 46.1%. Cotiza a 15.4 veces su flujo de caja libre (P/FCF) y a un PER de 30.1. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables del…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $2.28 | $1.60 | $-0.24 |
| Estimado | $2.32 | $1.82 | $1.52 | $2.20 |
| Sorpresa | — | +25.3% | +5.3% | -110.9% |
| Métrica | HALO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 83.6% | 57.0% | +26.6% |
| Operating Margin | 33.6% | -38.6% | +72.2% |
| Net Margin | 22.7% | -33.6% | +56.3% |
| FCF Margin | 46.1% | -13.9% | +60.0% |
| ROE | 649.2% | -40.4% | +689.6% |
| ROA | 12.6% | -32.0% | +44.6% |
| Current Ratio | 4.66 | 2.84 | +1.82 |
| Debt / Equity | 43.89 | 0.28 | +43.61 |